Advanced Oncotherapy announced that, further to the Company's announcement of 2 July 2018, Dr. Peter Sjostrand, Mr. Gabriel Urwitz, Mr. Chunlin Han, Mrs. RenHua Zhang and Dr. Yuelong Huang have been appointed as Non-Executive Directors, with immediate effect. Peter Sigurd Ivar Sjostrand, aged 72, owns no shares in the Company. Mr. Sjostrand has a long career as an independent Non-Executive Director for a number of public and private companies within the Healthcare, Industrial and Financial areas. Bo Gabriel Urwitz, aged 68, has an extensive background in industry and finance and has been involved with a large number of successful listed and private companies during his career. Gabriel co-founded Segulah Advisors AB in 1994 and was adjunct professor of financial economics at the Stockholm School of Economics from 1977 until 2002. Mr. Urwitz is a Director of AB Segulah, which owns 3.84% of the Company. Mr. Chunlin Han - Non-Executive Director Representing Liquid Harmony Ltd. which owns 29.9% of the Company, Chunlin Han, aged 25, is a Director of Hangzhou Ruilin Ynovo Investment Partners Ltd. which wholly owns Liquid Harmony Limited. Mr. Han is an executive Director of Liquid Harmony Ltd. and serves as Head of Investment and Financing for Realcan Pharmaceuticals Co. Ltd. Mrs. RenHua Zhang - Non-Executive Director Representing Liquid Harmony Ltd. which owns 29.9% of the Company, RenHua Zhang, aged 52, owns no shares in the Company although is considered to be acting in concert with Liquid Harmony Ltd. Mrs. Zhang is the co-Founder, CEO, and Vice Chairman of the board of Realcan Pharmaceutical Co. Ltd, a large distributor of medical drugs and equipment in China with access to more than 8,000 hospitals. Dr. Yuelong Huang - Non-Executive Director Representing Liquid Harmony Ltd. which owns 29.9% of the Company, Yuelong Huang, aged 41 owns no shares in the Company although is considered to be acting in concert with Liquid Harmony Ltd. Scientist by background, Mr. Huang serves as General Manager of Medical Technology Department of Realcan Pharmaceuticals Co. Ltd. where he is responsible for all M&A activities and medtech R&D/manufacturing.